Down syndrome preleukemia and leukemia

Pediatric Clinics of North America

Volumn 62, Issue 1, 2015, Pages 121-137

  Maloney, Kelly W ^a   Taub, Jeffrey W ^b   Ravindranath, Yaddanapudi ^b   Roberts, Irene ^c   Vyas, Paresh ^c  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

B ALL; Down syndrome; GATA1; Leukemia; Myeloid leukemia of Down syndrome; Preleukemia; Transient abnormal hematopoiesis transient myeloproliferative disorder

Indexed keywords

JANUS KINASE 2; TRANSCRIPTION FACTOR GATA 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CLINICAL FEATURE; CRLF2 GENE; DOWN SYNDROME; EXOME; GATA1 GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; HEMATOLOGIC DISEASE; HUMAN; JAK2 GENE; LEUKEMIA; LEUKEMOGENESIS; MOLECULAR PATHOLOGY; MYELOPOIESIS; PRELEUKEMIA; REVIEW; TRANSIENT ABNORMAL MYELOPOIESIS; TREATMENT OUTCOME; TRISOMY 21; BLOOD; CHILD; COMPLICATION; GENETICS; MUTATION; PRESCHOOL CHILD;

CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; HUMANS; LEUKEMIA; MUTATION; PRELEUKEMIA;

EID: 84915749961     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2014.09.009     Document Type: Review

References (97)

1. Krivit W., Good R.A. Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. AMA J Dis Child 1957, 94:289-293.
2. Tunstall-Pedoe O., Roy A., Karadimitris A., et al. Abnormalities in the myeloid compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood 2008, 112:4507-4511.
3. Chou S.T., Opalinska J.B., Yao Y., et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood 2008, 112:4503-4506.
4. Roy A., Cowan G., Mead A.J., et al. Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci USA 2012, 109:17579-17584.
5. Chou S.T., Byrska-Bishop M., Tober J.M., et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci USA 2012, 109(43):17573-17578.
6. Maclean G.A., Menne T.F., Guo G., et al. Altered hematopoiesis in trisomy 21 as revealed through invitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci USA 2012, 109(43):17567-17572.
7. Starc T.J. Erythrocyte macrocytosis in infants and children with Down syndrome. JPediatr 1992, 121:578-581.
8. Kivivuori S.M., Rajantie J., Siimes M.A. Peripheral blood cell counts in infants with Down's syndrome. Clin Genet 1996, 49:15-19.
9. Henry E., Walker D., Wiedmeier S.E., et al. Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. Am J Med Genet A 2007, 143:42-50.
10. Roberts I., Alford K., Hall G., et al. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood 2013, 122:3908-3917.
11. Korbel J.O., Tirosh-Wagner T., Urban A.E., et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci USA 2009, 106:12031-12036.
12. Alford K.A., Slender A., Vanes L., et al. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome. Blood 2010, 115:2928-2937.
13. Kirsammer G., Jilani S., Liu H., et al. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 2008, 111:767-775.
14. Stankiewicz M.J., Crispino J.D. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood 2009, 113:3337-3347.
15. Salek-Ardakani S., Smooha G., de Boer J., et al. ERG is a megakaryocytic oncogene. Cancer Res 2009, 69:4665-4673.
16. Malinge S., Bliss-Moreau M., Kirsammer G., et al. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. JClin Invest 2012, 122:948-962.
17. Chou S., Lodish H.F. Fetal liver hepatic progenitors are supportive stromal cells for hematopoietic stem cells. Proc Natl Acad Sci USA 2010, 107:7799-7804.
18. Klusmann J.H., Godinho F.J., Heitmann K., et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev 2010, 24:1659-1672.
19. Bourquin J.P., Subramanian A., Langebrake C., et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA 2006, 103:3339-3344.
20. Massey G.V., Zipursky A., Chang M.N., et al. Aprospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006, 107:4606-4613.
21. Klusmann J.H., Creutzig U., Zimmermann M., et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008, 111:2991-2998.
22. Roy A., Roberts I., Vyas P. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome. Semin Fetal Neonatal Med 2012, 17:196-201.
23. Wechsler J., Greene M., McDevitt M.A., et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002, 32:148-152.
24. Rainis L., Bercovich D., Strehl S., et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003, 102:981-986.
25. Hitzler J.K., Cheung J., Li Y., et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003, 101:4301-4304.
26. Xu G., Nagano M., Kanezaki R., et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 2003, 102:2960-2968.
27. Ahmed M., Sternberg A., Hall G., et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004, 103:2480-2489.
28. Toki T., Kanezaki R., Kobayashi E., et al. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome. Blood 2013, 121:3181-3184.
29. Hollanda L.M., Lima C.S., Cunha A.F., et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 2006, 38:807-812.
30. Sankaran V.G., Ghazvinian R., Do R., et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. JClin Invest 2012, 122:2439-2443.
31. Gamis A.S., Alonzo T.A., Gerbing R.B., et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood 2011, 118:6752-6759. [quiz: 996].
32. Pine S.R., Guo Q., Yin C., et al. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood 2007, 110:2128-2131.
33. Bull M.J. Health supervision for children with Down syndrome. Pediatrics 2011, 128:393-406.
34. Zipursky A. Transient leukaemia - a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 2003, 120:930-938.
35. Gamis A.S., Woods W.G., Alonzo T.A., et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. JClin Oncol 2003, 21:3415-3422.
36. James R., Lightfoot T., Simpson J., et al. Acute leukemia in children with Down's syndrome: the importance of population based study. Haematologica 2008, 93:1262-1263.
37. Hasle H., Abrahamsson J., Arola M., et al. Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia 2008, 22:1428-1430.
38. Zipursky A., Thorner P., De Harven E., et al. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 1994, 18:163-171.
39. Heerema-McKenney A., Arber D.A. Acute myeloid leukemia. Hematol Oncol Clin North Am 2009, 23:633-654.
40. Langebrake C., Creutzig U., Reinhardt D. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr 2005, 217:126-134.
41. Savasan S., Buck S., Raimondi S.C., et al. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: invitro drug sensitivity and outcome. Leuk Lymphoma 2006, 47:2076-2083.
42. Sorrell A.D., Alonzo T.A., Hilden J.M., et al. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer 2012, 118:4806-4814.
43. Forestier E., Izraeli S., Beverloo B., et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood 2008, 111:1575-1583.
44. Mercher T., Coniat M.B., Monni R., et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci USA 2001, 98:5776-5779.
45. Thiollier C., Lopez C.K., Gerby B., et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. JExp Med 2012, 209:2017-2031.
46. Gruber T.A., Larson Gedman A., Zhang J., et al. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 2012, 22:683-697.
47. Yoshida K., Toki T., Okuno Y., et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 2013, 45:1293-1299.
48. Nikolaev S.I., Santoni F., Vannier A., et al. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood 2013, 122:554-561.
49. Ravindranath Y., Abella E., Krischer J.P., et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992, 80:2210-2214.
50. Zeller B., Gustafsson G., Forestier E., et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005, 128:797-804.
51. Creutzig U., Reinhardt D., Diekamp S., et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005, 19:1355-1360.
52. Lange B.J., Kobrinsky N., Barnard D.R., et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 1998, 91:608-615.
53. Ravindranath Y., Yeager A.M., Chang M.N., et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. NEngl J Med 1996, 334:1428-1434.
54. Rao A., Hills R.K., Stiller C., et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006, 132:576-583.
55. Ravindranath Y., Taub J.W. Down syndrome and acute myeloid leukemia. Lessons learned from experience with high-dose Ara-C containing regimens. Adv Exp Med Biol 1999, 457:409-414.
56. O'Brien M.M., Taub J.W., Chang M.N., et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. JClin Oncol 2008, 26:414-420.
57. Kudo K., Kojima S., Tabuchi K., et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. JClin Oncol 2007, 25:5442-5447.
58. Al-Ahmari A., Shah N., Sung L., et al. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. Br J Haematol 2006, 133:646-648.
59. Tandonnet J., Clavel J., Baruchel A., et al. Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003. Pediatr Blood Cancer 2010, 54:927-933.
60. Blink M., Zimmermann M., von Neuhoff C., et al. Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica 2014, 99:299-307.
61. Loew T.M., Gamis A., Smith F.O., et al. Down syndrome patients with relapsed acute myelogenous leukemia. Blood 2004, 104. [abstract: 4526].
62. Taga T., Saito A.M., Kudo K., et al. Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood 2012, 120:1810-1815.
63. Muramatsu H., Sakaguchi H., Taga T., et al. Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. Pediatr Blood Cancer 2014, 61:925-927.
64. Caldwell J.T., Edwards H., Buck S.A., et al. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr Blood Cancer 2014, 61(10):1767-1773.
65. Wen Q., Goldenson B., Silver S.J., et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 2012, 150:575-589.
66. Stankov M.V., El Khatib M., Kumar Thakur B., et al. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 2014, 28:577-588.
67. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000, 110:512-524.
68. Robison L.L. Down syndrome and leukemia. Leukemia 1992, 6(Suppl 1):5-7.
69. Hasle H., Clemmensen I.H., Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000, 355:165-169.
70. Chessells J.M., Harrison G., Richards S.M., et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 2001, 85:321-325.
71. Dordelmann M., Schrappe M., Reiter A., et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 1998, 12:645-651.
72. Kalwinsky D.K., Raimondi S.C., Bunin N.J., et al. Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. Am J Med Genet Suppl 1990, 7:267-271.
73. Maloney K.W. Acute lymphoblastic leukaemia in children with Down syndrome: an updated review. Br J Haematol 2011, 155:420-425.
74. Whitlock J.A., Sather H.N., Gaynon P., et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2005, 106:4043-4049.
75. Bassal M., La M.K., Whitlock J.A., et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 2005, 44:21-28.
76. Pui C.H., Raimondi S.C., Borowitz M.J., et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. JClin Oncol 1993, 11:1361-1367.
77. Ragab A.H., Abdel-Mageed A., Shuster J.J., et al. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome. A Pediatric Oncology Group study. Cancer 1991, 67:1057-1063.
78. Buitenkamp T.D., Izraeli S., Zimmermann M., et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 2014, 123:70-77.
79. Arico M., Ziino O., Valsecchi M.G., et al. Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Cancer 2008, 113:515-521.
80. O'Connor D., Bate J., Wade R., et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood 2014, 124:1056-1061.
81. Maloney K.W., Larsen E., Mattano L.A., et al. Improvement in the Infection-related Mortality for Children with Down Syndrome (DS) in Contemporary Children's Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials. Pediatr Blood Cancer 2010, 54:787-864.
82. Maloney K.W., Carroll W.L., Carroll A.J., et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 2010, 116:1045-1050.
83. Hargrave D.R., Hann, Richards S.M., et al. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). Br J Haematol 2001, 112:293-299.
84. Izraeli S., Vora A., Zwaan C.M., et al. How I treat ALL in Down's syndrome: pathobiology and management. Blood 2014, 123:35-40.
85. Garre M.L., Relling M.V., Kalwinsky D., et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. JPediatr 1987, 111:606-612.
86. Peeters M.A., Rethore M.O., Lejeune J. Invivo folic acid supplementation partially corrects invitro methotrexate toxicity in patients with Down syndrome. Br J Haematol 1995, 89:678-680.
87. Taub J.W., Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 2005, 44:33-39.
88. Matloub Y., Bostrom B.C., Hunger S.P., et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011, 118:243-251.
89. Maloney K.W., Larsen E., Devidas M., et al. Event free (EFS) and overall survival (OS) for children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL) in Children's Oncology Group (COG) clinical trials AALL0232 and AALL0331. Pediatr Blood Cancer 2014, 61:S1-S104.
90. Meyr F., Escherich G., Mann G., et al. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. Br J Haematol 2013, 162:98-106.
91. Hertzberg L., Vendramini E., Ganmore I., et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115:1006-1017.
92. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41:1243-1246.
93. Cario G., Zimmermann M., Romey R., et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, 115:5393-5397.
94. Bercovich D., Ganmore I., Scott L.M., et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008, 372:1484-1492.
95. Mullighan C.G., Zhang J., Harvey R.C., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009, 106:9414-9418.
96. Harvey R.C., Mullighan C.G., Chen I.M., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.
97. Buitenkamp T.D., Pieters R., Gallimore N.E., et al. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012, 26:2204-2211.